Clinical trial

Randomized Double Blind Clinical Study on the Treatment of Bilateral Knee Arthrosis: Intra-articular Injection of Filtered Autologous Adipose Tissue Versus Placebo

Name
AdipoBil
Description
The purpose of the study is to assess the radiological and clinical outcomes comparing two different treatments (Filtered Autologous Adipose Tissue versus Placebo) in patients affecting bilateral knee osteoarthritis. After be randomized, every patient will be treated in both legs, one leg with Adipose Tissue and the other one with Placebo.
Trial arms
Trial start
2021-02-22
Estimated PCD
2022-04-22
Trial end
2025-10-01
Status
Recruiting
Treatment
injection of Filtered Autologous Adipose Tissue
Single injection of Filtered Autologous Adipose Tissue
Arms:
Filtered Autologous Adipose Tissue
Placebo
Single injection of Placebo
Arms:
Placebo
Size
100
Primary endpoint
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
12 months
Eligibility criteria
Inclusion Criteria: 1. bilateral degenerative chondropathy of the knees showing at least a grade 2-3 kellgren-lawrence classification (absence of severe osteoarthritis) 2. An overall Pain subscale score of the Western Ontario and McMaster Universities Osteoarthritis Index between a value of 9 and 19. 3. Failure, intended as the persistence of symptomatology, after at least one conservative treatment cycle (pharmacological, physiotherapeutic or infiltrative treatment); 4. Ability and informed consent of patients to actively participate in the rehabilitation protocol and clinical and radiological follow-up; Exclusion Criteria: 1. Patients incapable of understanding and wanting; 2. Diagnosis of leukaemia, known presence of metastatic malignant cells, ongoing or planned chemotherapy; 3. Diagnosis of rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis or arthritis resulting from another inflammatory disease; infection with human immunodeficiency virus (HIV), viral hepatitis; chondrocalcinosis; 4. Patients with uncontrolled diabetes mellitus; 5. Patients with uncontrolled thyroid metabolic disorders; 6. Patients who abuse alcoholic beverages, drugs or medicines; 7. Patients with misalignment of the lower limbs above 10 degrees; 8. Body Mass Index \> 40; 9. Pregnant or lactating state or intention to become pregnant during the period of participation in the study. 10. Patients with a history of trauma or intra-articular infiltration of therapeutic substances in the 6 months prior to screening. 11. Patients who have had knee surgery in the 12 months prior to screening. 12. Patients with insufficient abdominal adipose tissue, assessed by the investigator
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2023-07-19

1 organization

1 product

1 drug

2 indications